BioCardia (BCDA) Competitors $1.89 +0.03 (+1.61%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.85 -0.04 (-2.06%) As of 08/14/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. COEP, ACRV, CALC, PLUR, JSPR, OVID, STTK, ALXO, FGEN, and PEPGShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Coeptis Therapeutics (COEP), Acrivon Therapeutics (ACRV), CalciMedica (CALC), Pluri (PLUR), Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Coeptis Therapeutics Acrivon Therapeutics CalciMedica Pluri Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen Coeptis Therapeutics (NASDAQ:COEP) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media prefer COEP or BCDA? In the previous week, BioCardia had 11 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 14 mentions for BioCardia and 3 mentions for Coeptis Therapeutics. BioCardia's average media sentiment score of 0.61 beat Coeptis Therapeutics' score of 0.43 indicating that BioCardia is being referred to more favorably in the news media. Company Overall Sentiment Coeptis Therapeutics Neutral BioCardia Positive Which has preferable valuation & earnings, COEP or BCDA? BioCardia has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.98BioCardia$60K182.70-$7.95M-$1.85-1.02 Is COEP or BCDA more profitable? Coeptis Therapeutics' return on equity of -282.39% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% BioCardia N/A -19,117.42%-246.92% Do analysts prefer COEP or BCDA? BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,222.75%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, COEP or BCDA? Coeptis Therapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Do insiders & institutionals have more ownership in COEP or BCDA? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 20.0% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryBioCardia beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.79M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.0220.4930.2925.74Price / Sales182.70356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book-5.738.608.826.15Net Income-$7.95M-$54.65M$3.25B$265.06M7 Day Performance5.59%5.86%3.70%2.60%1 Month Performance-17.11%8.86%5.84%2.83%1 Year Performance-34.83%13.33%29.92%25.58% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.675 of 5 stars$1.89+1.6%$25.00+1,222.8%-27.0%$10.79M$60K-1.0240Earnings ReportShort Interest ↓Gap DownCOEPCoeptis Therapeutics0.497 of 5 stars$11.06-0.9%N/A+171.7%$39.21MN/A-1.912Earnings ReportShort Interest ↑ACRVAcrivon Therapeutics2.986 of 5 stars$1.23-0.8%$17.71+1,340.2%-80.2%$38.88MN/A-0.5558News CoverageEarnings ReportAnalyst ForecastGap UpCALCCalciMedica3.5326 of 5 stars$2.76+0.7%$16.00+479.7%-42.4%$38.28MN/A-1.7730Earnings ReportShort Interest ↓Gap UpPLURPluri2.236 of 5 stars$4.55-5.6%$12.00+163.7%-9.5%$37.91M$330K-0.82150Short Interest ↑JSPRJasper Therapeutics3.303 of 5 stars$2.63+7.3%$29.75+1,031.2%-83.1%$36.80MN/A-0.5020News CoverageEarnings ReportGap DownOVIDOvid Therapeutics4.4243 of 5 stars$0.56+7.9%$3.10+457.9%-16.8%$36.61M$570K-1.5960Trending NewsEarnings ReportShort Interest ↑Gap DownSTTKShattuck Labs3.7586 of 5 stars$0.74-2.3%$7.50+914.6%-72.4%$36.23M$5.72M-0.53100News CoveragePositive NewsAnalyst ForecastALXOALX Oncology2.9092 of 5 stars$0.61-9.2%$3.30+437.0%-74.6%$36.14MN/A-0.2540Earnings ReportFGENFibroGen4.6157 of 5 stars$8.37-3.9%$43.00+413.7%+4.6%$35.20M$29.62M-3.35570Earnings ReportHigh Trading VolumePEPGPepGen3.3371 of 5 stars$1.01-5.6%$7.67+659.1%-84.5%$35.10MN/A-0.3430Earnings ReportAnalyst Revision Related Companies and Tools Related Companies COEP Alternatives ACRV Alternatives CALC Alternatives PLUR Alternatives JSPR Alternatives OVID Alternatives STTK Alternatives ALXO Alternatives FGEN Alternatives PEPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access